MedTrace Logo

Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma

NCT01020812 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-07-27

Study results available
· View outcomes & findings →

Summary

To determine the efficacy and toxicity of TACE combined with SBRT

Conditions

  • Carcinoma, Hepatocellular
  • Hepatobiliary Neoplasm
  • Liver Carcinoma

Interventions

PROCEDURE

TACE

Standard of Care

PROCEDURE

SBRT

Standard of Care

Sponsors & Collaborators

Principal Investigators

  • Daniel T Chang · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020812 on ClinicalTrials.gov